Willow Biosciences: First Commercial Fermentation Of CBG Completed – The Daily Dive
Today on the Daily Dive, we sit down with that of Trevor Peters, CEO of Willow Biosciences (TSX: WLLW). Trevor joins us this afternoon to discuss the latest development at the firm – the completion of the first commercial fermentation run of cannabigerol, or CBG.
Willow Biosciences is a biotech firm focused on producing high purity cannabinoids for the treatment of a number of ailments. Its competitive edge for the market is focused around the method of production of cannabinoids, which does not occur via the traditional method of growing a plant. Instead, the firm biosynthesizes the compound via a yeast host, to produce a consistent, scalable and sustainable product.
FULL DISCLOSURE: Willow Biosciences Inc is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Willow Biosciences Inc on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.
As the founder of The Deep Dive, Jay is focused on all aspects of the firm. This includes operations, as well as acting as the primary writer for The Deep Dive’s stock analysis. In addition to The Deep Dive, Jay performs freelance writing for a number of firms and has been published on Stockhouse.com and CannaInvestor Magazine among others.
